Kronos Bio Announces Pipeline Update and p300 KAT Inhibitor Development Candidate
18 déc. 2023 16h06 HE
|
Kronos Bio, Inc.
Phase 1b portion of phase 1b/2 lanraplenib study in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia completed; review of data does not support continuing to phase 2 New...
Kronos Bio Announces Participation in H.C. Wainwright 4th Annual Precision Oncology Virtual Conference
04 déc. 2023 08h00 HE
|
Kronos Bio, Inc.
SAN MATEO, Calif. and CAMBRIDGE, Mass., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced...
Kronos Bio Announces Participation in 35th Annual Piper Sandler Healthcare Conference
27 nov. 2023 16h05 HE
|
Kronos Bio, Inc.
SAN MATEO, Calif. and CAMBRIDGE, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced...
Kronos Bio Reports Recent Business Progress and Third-Quarter 2023 Financial Results
13 nov. 2023 16h05 HE
|
Kronos Bio, Inc.
Company presented positive preliminary data from Phase 1 dose escalation portion of Phase 1/2 KB-0742 study at the AACR-NCI-EORTC and CTOS conferences Optimization of resource allocation,...
Kronos Bio Announces Plan to Optimize Resource Allocation, Restructure and Contain Costs Following Positive Preliminary Clinical Data from its KB-0742 Phase 1/2 Study
02 nov. 2023 16h05 HE
|
Kronos Bio, Inc.
Strategic resource allocation to fully explore KB-0742’s potential in both dose escalation and expansion cohorts across multiple tumor types in its ongoing Phase 1/2 study Restructuring plan extends...
Kronos Bio Presents Positive Preliminary Data from the Phase 1 Dose Escalation Portion of the Ongoing Phase 1/2 KB-0742 Study at the Connective Tissue Oncology Society Annual Meeting
02 nov. 2023 12h00 HE
|
Kronos Bio, Inc.
Brian Van Tine, M.D., of Washington University School of Medicine, shares data from the ongoing phase 1/2 KB-0742 clinical study that clearly corresponds with the findings from the pre-clinical...
Kronos Bio To Present Positive Preliminary Data from Phase 1 Dose Escalation Portion of Ongoing Phase 1/2 KB-0742 Study at the Connective Tissue Oncology Society Annual Meeting
27 oct. 2023 08h00 HE
|
Kronos Bio, Inc.
Brian Van Tine, M.D., of Washington University School of Medicine to share data from the ongoing Phase 1/2 study at leading international sarcoma meeting SAN MATEO, Calif., and CAMBRIDGE, Mass., Oct....
Kronos Bio Presents Positive Preliminary Data from Phase 1 Dose Escalation Portion of Phase 1/2 KB-0742 Study at AACR-NCI-EORTC
13 oct. 2023 12h30 HE
|
Kronos Bio, Inc.
Demonstrated on-mechanism, single agent anti-tumor activity in heavily pre-treated patients with transcriptionally addicted solid tumors Showed manageable safety profile, with no grade 3/4...
Kronos Bio To Present Interim Data from Phase 1 Dose Escalation Portion of Ongoing Phase 1/2 KB-0742 Study at AACR-NCI-EORTC and Host Virtual Investor Event on October 13
04 oct. 2023 16h05 HE
|
Kronos Bio, Inc.
SAN MATEO, Calif., and CAMBRIDGE, Mass., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced...
Kronos Bio Announces Departure of Chief Financial Officer and Head of Corporate Development
17 août 2023 08h00 HE
|
Kronos Bio, Inc.
SAN MATEO, Calif. and CAMBRIDGE, Mass., Aug. 17, 2023 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, announced that...